A systemic reviewpublished inNeuroToxicologydetermined that cannabidiol  (CBD) has potential in the treatment of substance use disorders, chronic psychosis, and anxiety.

The review considered 27 articles, all randomized controlled trials (RCTs). The abstract of the article notes that “There is currently limited evidence regarding the safety and efficacy of CBD for the treatment of psychiatric disorders,” but that the potential shown in the trials considered warrants “further large-scale RCTs… to better evaluate the efficacy of CBD in both acute and chronic illnesses, special categories, as well as to exclude any possible abuse liability.”
Related: Study: PlusCBD Oil Helps Improve Sleep, Reduce Appetite CBD Industry to Increase 706% Through 2023, Report Predicts  Scientists ID CBD as a “Powerful New Antibiotic”